Topotecan, a topoisomerase I inhibitor, was evaluated in a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel.

Bookman, M., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J., et al. (1998). Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. JOURNAL OF CLINICAL ONCOLOGY, 16(10), 3345-3352.

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

LISSONI, ANDREA ALBERTO;
1998

Abstract

Topotecan, a topoisomerase I inhibitor, was evaluated in a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel.
Articolo in rivista - Articolo scientifico
Treatment Outcome; Thrombocytopenia; Middle Aged; Female; Paclitaxel; Neoplasm Recurrence, Local; Leukopenia; Neutropenia; Humans; Carcinoma; Antineoplastic Agents; Ovarian Neoplasms; Carboplatin; Topotecan; Aged; Adult; Drug Administration Schedule; Cisplatin
English
3345
3352
Bookman, M., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J., et al. (1998). Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. JOURNAL OF CLINICAL ONCOLOGY, 16(10), 3345-3352.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/29415
Citazioni
  • Scopus 317
  • ???jsp.display-item.citation.isi??? 270
Social impact